首頁/BSX

公开研究页

行情来自市场数据接口；下方公司研究基于已核验公开来源，但不等同于实时、个性化的 AI 投资结论。

去工作台分析 BSX
BSXNYSE/health care

Boston Scientific Corporation

$44.65下跌-0,12 (-0,27%)
研究复核截至: 2026年7月12日 上午12:00 [UTC]
研究概览近 3 个月价格投资论点关键催化剂最新财报研究近期新闻数据与研究来源

研究概览

Boston Scientific Corporation operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
45,34
Haut
45,43
Bas
44,36
Capitalisation
66,37 Md
Ratio C/B
18.68
Plus haut sur 52 semaines
--
Dividende
--
Dividende trimestriel
--

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景
FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. The base case remains conditional on regulatory and clinical risk staying manageable.
多头情景
FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications. A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.
空头情景
Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms. Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio. Large rivals and new technologies can pressure pricing, physician loyalty and market share.
论点失效条件
Reassess the thesis if trial outcomes, approval delays or safety signals can slow adoption of important growth platforms.

关键催化剂

  • Pulsed-field ablation

    FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand.

  • Structural-heart adoption

    WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications.

  • New-product pipeline

    A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

主要风险

  • Regulatory and clinical risk

    Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms.

  • Portfolio integration

    Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio.

  • Device competition

    Large rivals and new technologies can pressure pricing, physician loyalty and market share.

最新财报研究

Q1 2026

Boston Scientific's first-quarter 2026 update reflected broad organic growth across cardiovascular and MedSurg franchises, continued product-launch momentum and integration activity while management maintained its growth outlook.

估值解读

  • A growth premium depends on durable procedure expansion and multiple platforms contributing rather than reliance on one launch cycle.
  • Pipeline optionality should be discounted for clinical, reimbursement and acquisition-integration risk.

同行比较入口

ABTISRGSYK

近期新闻

StockStory · il y a 16 heures

1 Stock Under $50 to Keep an Eye On and 2 We Brush Off

Insider Monkey · hier

Boston Scientific Corporation (BSX) Is A Stock To Buy According To D. E. Shaw

Zacks · il y a 4 jours

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

Trefis · il y a 5 jours

The Wide Chasm Priced Into Boston Scientific Stock

MedTech Dive · il y a 5 jours

J&J wins FDA approval for dual-energy ablation catheter

Motley Fool · il y a 5 jours

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock

数据与研究来源

研究更新: 2026年7月12日 上午12:00 [UTC]
3 个已核验来源
Q1 2026 Earnings Release and Financial ResultsBoston Scientific Corporation · earnings已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/22 上午12:00:00

查看原始来源
Boston Scientific Corporation Investor RelationsBoston Scientific Corporation · company已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

查看原始来源
Boston Scientific SEC filings and company factsU.S. Securities and Exchange Commission · filing已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/4/22 上午12:00:00

查看原始来源

在工作台中继续研究

保留 BSX，运行多智能体分析并持续跟踪论点变化。

免费分析 BSX

探索完整研究體系

每個階段職責明確，並為下一階段留下可追溯的輸出。

研究方法論閱讀市場報告瀏覽股票

继续深挖这只股票

市場分析 Agent

負責先判断价格結構、趋势强弱與交易節奏有没有支持 thesis。

基本面分析 Agent

負責判断公司的业务质量、盈利結構與财务健康度。

新闻分析 Agent

追踪最近发生了什么，以及這些事件是否真的改变 thesis。

風險经理 Agent

負責在風險辩論后给出最终風險等級和执行邊界。